BRIEF published on 10/02/2026 at 00:40, 21 days 11 hours ago Medicure octroie des options d'achat d'actions à son personnel clé Options D'achat D'actions Medicure Inc. Marché Américain Médicaments Approbation De La TSX
BRIEF published on 10/02/2026 at 00:40, 21 days 11 hours ago Medicure Grants Stock Options to Key Personnel Stock Options Pharmaceuticals Medicure Inc. U.S. Market TSX Approval
PRESS RELEASE published on 10/02/2026 at 00:35, 21 days 11 hours ago Medicure Announces Grant of Stock Options Medicure Inc. grants stock options to directors, officers, employees, and consultants, aiming at the development and commercialization of pharmaceuticals in the US market Stock Options Pharmaceuticals Medicure Inc. US Market Healthcare Products
BRIEF published on 09/29/2026 at 00:05, 24 days 12 hours ago Medicure termine le recrutement pour l'essai clinique de phase 3 MEND-PNPO Essai Clinique Approbation De La FDA MC-1 Médecine Déficit En PNPO
BRIEF published on 09/29/2026 at 00:05, 24 days 12 hours ago Medicure Completes Enrollment in MEND-PNPO Phase 3 Clinical Trial FDA Approval Clinical Trial Medicure MC-1 PNPO Deficiency
PRESS RELEASE published on 09/29/2026 at 00:00, 24 days 12 hours ago Medicure Announces Completion of Enrollment in Its MEND-PNPO Phase 3 Clinical Trial Medicure completes patient enrollment in MEND-PNPO Phase 3 study evaluating MC-1 for PNPO deficiency. Study progress discussed, including FDA designations and future conference presentations Medicure MC-1 PNPO Deficiency MEND-PNPO FDA Designations
BRIEF published on 09/09/2026 at 00:30, 1 month 14 days ago Medicure dévoile les données de son étude de phase 3 au Congrès européen de l'épilepsie Medicure Inc. Étude MEND-PNPO Déficit En PNPO Essai MC-1 Congrès Sur L'épilepsie
BRIEF published on 09/09/2026 at 00:30, 1 month 14 days ago Medicure Unveils Phase 3 Study Data at European Epilepsy Congress Medicure Inc. PNPO Deficiency MEND-PNPO Study MC-1 Trial Epilepsy Congress
PRESS RELEASE published on 09/09/2026 at 00:25, 1 month 14 days ago Medicure Presents MEND-PNPO Phase 3 Study Design and Baseline Data at the 16th European Epilepsy Congress Medicure Inc. presents design and data from MEND-PNPO Phase 3 study on PNPO deficiency treatment at European Epilepsy Congress. Not FDA-approved yet Clinical Trials Drug Development Medicure Inc. PNPO Deficiency MEND-PNPO
BRIEF published on 08/14/2026 at 23:05, 2 months 8 days ago Medicure annonce ses résultats financiers du deuxième trimestre 2026 et la tenue d'une prochaine conférence téléphonique. Résultats Financiers Medicure Inc. Augmentation Des Revenus ZYPITAMAG® Segment Pharmaceutique
Published on 10/23/2026 at 02:20, 9 hours 55 minutes ago Apex Announces Nasdaq Listing and Pricing of US$1.86 Million Offering
Published on 10/22/2026 at 23:30, 12 hours 45 minutes ago Cypher Announces Subscription Receipt Offering
Published on 10/22/2026 at 22:30, 13 hours 45 minutes ago Unusual Machines to Announce Third Quarter 2026 Financial Results and Provide Corporate Update
Published on 10/22/2026 at 16:00, 20 hours 15 minutes ago Future Fuels Announces Closing of Brokered Offering for Gross Proceeds of C$6.6 Million
Published on 10/22/2026 at 14:30, 21 hours 45 minutes ago Unusual Machines Receives $16.9 Million Purchase Order from Powerus for American-Made Drone Components
Published on 10/23/2026 at 11:45, 30 minutes ago Original-Research: Grand City Properties SA (von First Berlin Equity Research GmbH): Kaufen
Published on 10/23/2026 at 11:30, 45 minutes ago Bulgarian Financial Supervision Commission completes preliminary review of the voluntary public takeover offer for Shelly Group SE
Published on 10/23/2026 at 11:30, 45 minutes ago Acceptance period of Sazerac’s voluntary public takeover offer for Berentzen-Gruppe Aktiengesellschaft commences
Published on 10/23/2026 at 11:00, 1 hour 15 minutes ago Annual General Meeting Approves Contribution: Innok Robotics on Course for the Public Capital Market
Published on 10/23/2026 at 07:00, 5 hours 15 minutes ago Safran publie son chiffre d’affaires du 3e trimestre 2026
Published on 10/22/2026 at 18:00, 18 hours 15 minutes ago THERMADOR GROUPE : Completion of the share buy-back programme launched in August
Published on 10/22/2026 at 18:00, 18 hours 15 minutes ago THERMADOR GROUPE : Fin du programme de rachat d’actions débuté en août
Published on 10/22/2026 at 18:00, 18 hours 15 minutes ago bioMérieux receives Dual 510(k) Clearance and CLIA Waiver from the FDA for the BIOFIRE® SPOTFIRE® Vaginitis Panel to Advance Women’s Health with Rapid Molecular Diagnostics
